Antioxidants in bipolar disorder: A double blind randomised placebo controlled trial of n-acetyl cysteine.

Phase 3

Completed

• Conditions: Bipolar disorder; Mental Health - Other mental health disorders; Neurological - Other neurological disorders

• Registration Number: ACTRN12605000362695
• Lead Sponsor: Research Funds

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

DSM-IV diagnosis of bipolar disorder (I, II or NOS), have had at least one mood episode within the last 12 months, have been on stable treatment for one month, have the capacity to consent and be on effective contraception.

Exclusion Criteria

Asthma, history of ulcers, respiritory insufficiency, any current systemic medical disorder, participants who are currently taking either 500mg of NAC/day, 200ug of selenium/day or 500 IU of Vitamin E/day and women pregnant or lactacting.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to intervention for mood episode[When occurred]

Secondary Outcome Measures

Name	Time	Method
YMRS[At each trial visit. (Total of nine visits).];BDRS[At each trial visit. (Total of nine visits).];Q-LES-Q[At each trial visit. (Total of nine visits).];Slice/life[At each trial visit. (Total of nine visits).];Life/rift[At each trial visit. (Total of nine visits).];SOFAS[At each trial visit. (Total of nine visits).];CGI [At each trial visit. (Total of nine visits).];GAF[At each trial visit. (Total of nine visits).]